Skip to main content

Cue Biopharma, Inc.

corporate_fare Company Profile

Cue Biopharma, Inc.

CUE·NASDAQ·Life Sciences·CIK 0001645460

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a new class of injectable therapeutics. These therapeutics are engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. The company's Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, aiming to enhance efficacy while minimizing off-target effects. Cue Biopharma's programs include several drug product candidates: * **CUE-400 series (Autoimmune Diseases):** These candidates, such as CUE-401 for autoimmune conditions, exploit transforming growth factor beta (TGF-β) and Interleukin 2 (IL-2) signaling. Their mechanism is designed to induce an anti-inflammatory process by fostering the proliferation of regulatory T cells (Tregs) and inducing Tregs from T effector cells, with the potential to restore immune balance and functional immune tolerance. * **CUE-500 series (Targeted Cell Depletion):** An example is CUE-501 for autoimmune B cell depletion, which has been licensed to Boehringer Ingelheim International GmbH. These candidates redirect anti-viral killer T cells to target and eliminate defined pathogenic cells. * **CUE-100 series (Oncology):** This series includes CUE-101 for HPV+ cancers and CUE-102 for Wilms' tumor 1 protein (WT1) expressing cancers. Both of these have been licensed to ImmunoScape Pte. Ltd. for development in oncology indications and are designed to selectively activate and expand tumor-specific T cells. The Immuno-STAT framework is engineered to be highly flexible and modular, allowing for the deployment of similar core functional elements to restore immune balance across various therapeutic approaches.

Cue Biopharma, Inc. (NASDAQ:CUE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for CUE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for CUE spans 8-K, 10-Q, 4, S-3.

Recent high-impact activity:

  • Cue Biopharma Posts $50M Q3 Loss, $57.9M Cash, New CUE-221 Subgroup Data
  • Cue Biopharma Posts $50M Third-Quarter Loss
  • CUE-221 Phase 2 CSU Data: 54% Complete Hives Resolution vs 11% Placebo, Durable 12 Weeks Off Drug
  • Cue Biopharma Surges 51% Premarket on Positive Phase 2 CSU Data
  • Cue Biopharma's CUE-221 Hits Primary Endpoint in Phase 2 CSU Trial, Beats Xolair

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$27.47M
Net Income
-$26.6M
Diluted EPS
-$0.28
Op. Cash Flow
-$21.69M
Free Cash Flow
-$21.86M
Operating Income
-$26.55M
Cash & Equivalents
$27.14M
Debt / Equity
0.00×
Net Margin
-96.9%
Shares Outstanding
96.62M sh
Source: 10-K · filed 2026-03-16 · accession 0001193125-26-108287

Short Interest & Short Volume

7.57 days to cover

FINRA reported short interest of 862,798 shares in CUE as of the October 30, 2026 settlement, a 8.9% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 50.1% of CUE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)862,798 shares as of October 30, 2026
Change vs prior period▲ 8.9%
Days to cover7.57 at avg daily volume of 113,963
Daily short volume (FINRA facilities)50.1% of 389,479 shares on November 20, 2026
5-day average short volume55.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CUE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.

3 shelf registrations

$50M Private Placement · Dilution Impact

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$4.2 +1.20% today
52-week range · as of 2026-11-16 $4.2 – $45.5
Market cap
$34.69M
Volume
1.3M (1.5× avg)
3-mo avg 831.6K
Live data · 2026-11-22 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CUE - Latest Insights

CUE
Nov 16, 2026, 4:52 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $4.20 info
Change: -$9.60 (-70%) info
Market Cap: $34.692M info
CUE
Nov 16, 2026, 4:48 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $4.20 info
Change: -$9.90 (-70%) info
Market Cap: $34.692M info
CUE
Sep 21, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $47.67
Real-time Price: $4.20 info
Change: -$43.47 (-91%) info
Market Cap: $34.692M info
CUE
Sep 21, 2026, 6:59 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $61.10
Real-time Price: $4.20 info
Change: -$56.90 (-93%) info
Market Cap: $34.692M info
CUE
Sep 20, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.63
Real-time Price: $4.20 info
Change: -$33.43 (-89%) info
Market Cap: $34.692M info
CUE
Aug 14, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.03
Real-time Price: $4.20 info
Change: -$26.83 (-86%) info
Market Cap: $34.692M info
CUE
Aug 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.06
Real-time Price: $4.20 info
Change: -$28.86 (-87%) info
Market Cap: $34.692M info
CUE
Aug 14, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.20
Real-time Price: $4.20 info
Change: -$30.00 (-88%) info
Market Cap: $34.692M info
CUE
Jul 10, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $36.77
Real-time Price: $4.20 info
Change: -$32.57 (-89%) info
Market Cap: $34.692M info
CUE
Jul 10, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.77
Real-time Price: $4.20 info
Change: -$32.57 (-89%) info
Market Cap: $34.692M info
CUE
Jul 10, 2026, 10:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $40.40
Real-time Price: $4.20 info
Change: -$36.20 (-90%) info
Market Cap: $34.692M info
CUE
Jul 09, 2026, 9:40 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $36.77
Real-time Price: $4.20 info
Change: -$32.57 (-89%) info
Market Cap: $34.692M info
CUE
Jun 03, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $26.91
Real-time Price: $4.20 info
Change: -$22.71 (-84%) info
Market Cap: $34.692M info
CUE
Jun 03, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.91
Real-time Price: $4.20 info
Change: -$22.71 (-84%) info
Market Cap: $34.692M info
CUE
Jun 03, 2026, 4:06 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $26.91
Real-time Price: $4.20 info
Change: -$22.71 (-84%) info
Market Cap: $34.692M info
CUE
Jun 02, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.00
Real-time Price: $4.20 info
Change: -$23.80 (-85%) info
Market Cap: $34.692M info
CUE
May 21, 2026, 8:51 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $19.90
Real-time Price: $4.20 info
Change: -$15.70 (-79%) info
Market Cap: $34.692M info
CUE
May 15, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.01
Real-time Price: $4.20 info
Change: -$20.81 (-83%) info
Market Cap: $34.692M info
CUE
May 14, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $25.35
Real-time Price: $4.20 info
Change: -$21.15 (-83%) info
Market Cap: $34.692M info
CUE
May 14, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $25.35
Real-time Price: $4.20 info
Change: -$21.15 (-83%) info
Market Cap: $34.692M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets